13 completed, 6 terminated, 3 recruiting. 9 Phase 2, 9 Phase 4, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 2, Recruiting 1 |
| Phase 4 | 9 | Completed 4, Terminated 4, Recruiting 1 |
| Phase 3 | 3 | Completed 2, Recruiting 1 |
Follow patiromer: new trials by email Literature Review of patiromer trials Research Report on patiromer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patiromer and Diet/hrQoL in Chronic Dialysis Patiromer 8400 MG [Veltassa], Placebo - Hyperkalaemia, Chronic Kidney Disease Stage 3 and 4 | Phase 3 | Recruiting | Mario Negri Institute for Pharmacological Research | 40 | 2025-07-08 | 2025-09-04 |
| Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels Patiromer - Hyperkalemia | Phase 2 | Recruiting | Vifor Pharma, Inc. | 36 | 2025-04-06 | 2026-09-25 |
| Potassium Correction for RAAS Optimization in Chronic Kidney Disease Patiromer 8400 MG [Veltassa], Placebo - Chronic Kidney Diseases, Hyperkalemia | Phase 4 | Recruiting | University Medical Center Groningen | 44 | 2024-04-01 | 2025-12-19 |
| Comparison of Potassium Binders in the ER Polyethylene Glycol 3350, Sodium Polystyrene Sulfonate Oral Suspension [SPS], Patiromer - Acute Hyperkalemia, Oral Potassium Binders | Phase 4 | Terminated | University of California, Irvine | 37 | 2020-10-20 | 2026-04-22 |
| Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management Patiromer Powder for Oral Suspension [Veltassa], Placebo - Hyperkalemia | Phase 4 | Terminated | Comprehensive Research Associates | 115 | 2020-10-08 | 2023-08-31 |
| RELieving Increasing oEdema Due to Heart Failure Patiromer - Heart Failureļ¼Congestive | Phase 4 | Terminated | NHS Greater Glasgow and Clyde | 19 | 2020-08-26 | 2025-03-04 |
| Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) Patiromer, Placebos - Hyperkalemia | Phase 3 | Completed | Vifor Pharma, Inc. | 1195 | 2019-04-24 | 2023-02-24 |
| Exploratory Study of ZG-801 for the Treatment of Hyperkalemia patiromer, placebo - Hyperkalemia | Phase 2 | Completed | Zeria Pharmaceutical | 184 | 2019-02-18 | 2021-03-25 |
| Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On Spironolactone - Type2 Diabetes, Hyperkalemia | Phase 4 | Terminated | University Hospitals Cleveland Medical Center | 8 | 2018-07-17 | 2022-05-16 |
| Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet. Patiromer, Research Diet Menu - Chronic Kidney Diseases, Hyperkalemia | Phase 4 | Completed | NYU Langone Health | 3 | 2018-03-12 | 2021-12-01 |
| The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia Patiromer - ESRD, Hyperkalemia | Phase 2 | Completed | Dominic Raj | 27 | 2017-11-01 | 2023-05-09 |
| Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer Patiromer - Hyperkalemia, Kidney Transplant | Phase 4 | Completed | The Rogosin Institute | 8 | 2017-08-01 | 2020-04-13 |
| Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia Patiromer - Hyperkalemia | Phase 2 | Terminated | Vifor Pharma, Inc. | 23 | 2017-07-07 | 2022-10-19 |
| Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease Patiromer, Placebo, Spironolactone - Hyperkalemia, Resistant Hypertension | Phase 2 | Completed | Relypsa, Inc. | 295 | 2017-01-23 | 2021-05-12 |
| High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure Spironolactone and patiromer - Acute Decompensated Heart Failure | Completed | The University of Texas Health Science Center at San Antonio | 48 | 2016-09-01 | 2019-05-03 | |
| Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE) Patiromer 25.2 g - Kidney Failure, Chronic | Phase 4 | Completed | Baylor College of Medicine | 43 | 2016-08-01 | 2019-05-09 |
| Patiromer With or Without Food for the Treatment of Hyperkalemia patiromer - Hyperkalemia | Phase 4 | Completed | Relypsa, Inc. | 114 | 2016-02-01 | 2021-05-12 |
| A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) Patiromer, Placebo - Chronic Kidney Disease (CKD), Hyperkalemia (HK) | Phase 3 | Completed | Relypsa, Inc. | 243 | 2013-02-01 | 2021-06-03 |
| Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) patiromer, losartan, spironolactone - Chronic Kidney Disease, Hypertension | Phase 2 | Completed | Relypsa, Inc. | 324 | 2011-06-01 | 2021-06-03 |
| Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease patiromer, spironolactone - Heart Failure | Phase 2 | Completed | Relypsa, Inc. | 63 | 2010-05-01 | 2021-05-12 |
Showing 20 of 22. Sign in to see all of them.
Hyperkalemia (18) · Renal Insufficiency, Chronic (11) · Heart Failure (4) · Hypertension (4) · Emergencies (2) · Kidney Failure, Chronic (2) · Diabetic Nephropathies (1)
Relypsa, Inc. (7) · Vifor Pharma, Inc. (3) · Baylor College of Medicine (1) · Comprehensive Research Associates (1) · Dominic Raj (1) · Mario Negri Institute for Pharmacological Research (1) · NHS Greater Glasgow and Clyde (1) · NYU Langone Health (1) · The Rogosin Institute (1) · The University of Texas Health Science Center at San Antonio (1) · University Hospitals Cleveland Medical Center (1) · University Medical Center Groningen (1) · University of California, Irvine (1) · Zeria Pharmaceutical (1)
United States (16) · Georgia (7) · Ukraine (5) · Germany (4) · Hungary (4) · Italy (4) · Poland (4) · Bulgaria (3) · Croatia (3) · Czechia (3) · Serbia (3) · Slovenia (3) · United Kingdom (3) · Belgium (2) · Canada (2)
Julian Platon, MD, PhD (2) · Aaltje Adema, dr. (1) · David Goldfarb, MD (1) · Femke Waanders, dr. (1) · John Cleland (1) · Jun Lee, MD (1) · Liffert Vogt, prof. dr. (1) · Martin de Borst, prof. dr. (1) · Sanjay Rajagopalan, MBBS (1) · Shweta Bansal (1) · Zubaid Rafique, MD (1)
PMID 32588430, PMID 21208974, PMID 29369537, PMID 29767459, PMID 30176673, PMID 31533906, PMID 32750456, PMID 33608263, PMID 34136782, PMID 35369022, PMID 35900838, PMID 37016309, PMID 37308268, PMID 39159624, PMID 39340493, PMID 41730555, PMID 41957746
2016 (2), 2018 (2), 2023 (1), 2025 (1)